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Summary. Background: Among acutely ill hospitalized medical patients, extended-duration thromboprophylaxis reduces the risk of venous thromboembolism (VTE), but some pharmacologic strategies have been associated with greater risks of major bleeding, thereby offsetting the net clinical benefit (NCB). Methods: To assess the risk-benefit profile of anticoagulation regimens, a previously described bivariate method that does not assume a linear risk-benefit tradeoff and can accommodate different margins for efficacy and safety was performed to simultaneously assess efficacy (symptomatic VTE) and safety (major bleeding) on the basis of data from four randomized controlled trials of extended-duration (30-46 days) versus standard-duration (6-14 days) thromboprophylaxis among 28 227 patients (EXCLAIM, ADOPT, MAGEL-LAN and APEX trials). Results: Extended thromboprophylaxis with full-dose betrixaban (80 mg once daily) was superior in efficacy and non-inferior in safety to standard-duration enoxaparin, and showed a significantly favorable NCB, with a risk difference of À 0.51% (À 0.89% to À 0.10%) in the bivariate outcome. Extended enoxaparin was superior in efficacy and inferior in safety (bivariate outcome: 0.03% [À 0.37% to 0.43%]), whereas apixaban and rivaroxaban were non-inferior in efficacy and inferior in safety (À 0.20% [À 0.49% to 0.17%] and 0.23% [À 0.16% to 0.69%], respectively). Reduced-dose betrixaban did not show a significant difference in either efficacy or safety (0.41% [À 0.85% to 1.94%]). Conclusions: In a bivariate analysis that assumes non-linear risk-benefit tradeoffs, extended prophylaxis with full-dose betrixaban was superior to standard-duration enoxaparin, whereas other regimens failed to simultaneously achieve both superiority and non-inferiority with respect to symptomatic VTE and major bleeding in the management of acutely ill hospitalized medical patients.
Introduction
Among hospitalized medically ill patients at risk of venous thromboembolism (VTE), standard pharmacologic thromboprophylaxis is recommended during the period of immobilization or acute hospital stay [1] . The risk of VTE may, however, extend well beyond this brief standard course of anticoagulation, and may remain elevated for weeks to months after hospital discharge [2] . As compared with standard-duration thromboprophylaxis, extended-duration therapy with a novel oral anticoagulant may reduce the risk of symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE), but may also increase the risk of major bleeding, offsetting the net clinical benefit (NCB) of such a strategy [3] .
Clinical decisions regarding the utility of thromboprophylaxis require the simultaneous consideration of both efficacy and safety outcome. The conventional approach to net clinical benefit makes three assumptions: (i) it assumes a linear relationship between safety and efficacy; (ii) it assumes that there is no upper limit or boundary to the rate of safety outcome that would be acceptable; and (iii) it assumes that both efficacy and safety will be subjected to the same statistical margins in the testing of either superiority or non-inferiority.
To overcome the limitations of this linear NCB framework, a novel bivariate approach that considers a multiplicative definition of NCB has been proposed [4] . A bivariate model does not assume a static, linear relationship between safety and efficacy: the magnitude of efficacy required to offset a safety signal may increase dramatically and non-linearly as the absolute risk of bleeding rises, for example. Whereas a conventional NCB would use either a simple composite endpoint where efficacy and safety endpoints are weighed 1 : 1 (Fig. S1 ) or at a ratio of 2 : 1, for instance (Fig. S2) , both of these ratios are constant over any given range of efficacy or safety [5] . Under the bivariate framework, this tradeoff is not fixed, and varies non-linearly according to the absolute risk difference in efficacy and safety (Fig. S3) . Although Figs S1 and S2 show different slopes for the tradeoff between efficacy and safety, both are straight lines. In contrast, Fig. S3 shows that, in a bivariate analysis, there is a curvilinear tradeoff between efficacy and safety. Stated differently, the acceptable tradeoff between efficacy and safety varies widely according to the rates of efficacy and safety (more specifically the risk difference in efficacy and safety).
Second, in contrast to the conventional method, in a bivariate analysis a boundary is set for the difference in bleeding between the two strategies that would be clinically acceptable. These are shown by solid circles at the limits of the curves in Fig. S3 . Simply stated, these solid circles indicate the upper limit of excess bleeding and excess efficacy events that would be clinically acceptable (Fig. S3) .
Finally, not only is the relationship between efficacy and safety curvilinear, as stated above, but this curvilinear relationship is, in fact, asymmetric. As shown in Fig. S3 , the distance from the x-axis to the curve (the length of the green arrow; the amount of acceptable difference in efficacy) is different from the distance from the y-axis to the curve (the length of the red arrow; the amount of acceptable difference in safety). Stated simply, there is asymmetry in the amount of efficacy versus safety that is clinically acceptable. In a bivariate analysis, the margins for efficacy and safety can be tailored in an asymmetric fashion to reflect the clinical relevance of the respective endpoints. The researcher can decide to set parameters to assess whether a new therapy is superior in efficacy and simultaneously non-inferior with respect to safety, or alternatively whether a regimen is significantly safer (superior in safety) and simultaneously non-inferior with respect to efficacy.
The bivariate method has been employed to evaluate the risk-benefit profile of the anticoagulation strategy in various settings [6] [7] [8] . In this study, the bivariate approach was applied to simultaneously analyze the risk and benefit of extended-duration thromboprophylaxis among acutely ill hospitalized medical patients on the basis of the published results of four phase III/IV randomized controlled trials (EXCLAIM, ADOPT, MAGELLAN, and APEX) [9] [10] [11] [12] . The effects of extended-duration enoxaparin, apixaban, rivaroxaban and betrixaban on symptomatic VTE and major bleeding were compared in a bivariate model to assess their risk-benefit profile.
Methods

Data extraction
Randomized controlled trials were selected if they fulfilled all of the following criteria: (i) the study population comprised patients hospitalized for an acute medical illness, including heart failure, respiratory failure, infectious disease, rheumatic disorder, or ischemic stroke; (ii) the study design entailed comparison between extended-duration (30-46 days) and standard-duration (6-14 days) pharmacologic thromboprophylaxis; and (iii) the primary study endpoints included symptomatic DVT, PE, VTE-related mortality, and major bleeding. Four phase III/IV randomized controlled trials met these criteria and were included in the study: EXCLAIM [9] , ADOPT [10] , MAGELLAN [11] , and APEX [12] .
Study interventions and endpoints
The EXCLAIM trial Following open-label subcutaneous enoxaparin 40 mg once daily for 10 AE 4 days, 6085 patients were randomized in a 1 : 1 ratio to receive either enoxaparin or placebo for an additional 28 AE 4 days [9] . The primary efficacy endpoint was VTE, defined as a composite of symptomatic or asymptomatic proximal DVT, symptomatic PE or fatal PE during the doubleblind treatment period (28 AE 4 days after random assignment). The primary safety endpoint was the incidence of major hemorrhagic complications during and up to 48 h after the double-blind treatment period.
The ADOPT trial A total of 6528 patients were randomized in a 1 : 1 ratio to receive either oral apixaban 2.5 mg twice daily for 30 days or subcutaneous enoxaparin 40 mg once daily during their hospital stay, for a minimum of 6 days [10] . The primary efficacy endpoint was a composite of asymptomatic proximal DVT, symptomatic DVT, fatal or non-fatal PE or death related to VTE in the 30-day treatment period. Major bleeding during the 30-day treatment period was included as one of the main safety endpoints.
The MAGELLAN trial A total of 8101 patients were randomized in a 1 : 1 ratio to receive either oral rivaroxaban 10 mg once daily for 35 AE 4 days or subcutaneous enoxaparin 40 mg once daily for 10 AE 4 days [11] . The primary efficacy endpoint was a composite of asymptomatic proximal DVT, symptomatic proximal or distal DVT, symptomatic non-fatal PE, or death related to VTE. Major bleeding was included in the safety outcome measures. Data on efficacy and safety endpoints up to 35 days were extracted for the purpose of homogeneity.
The APEX trial A total of 7513 patients were randomized in a 1 : 1 ratio to receive either oral betrixaban 80 mg once daily (full-dose regimen) for 35-42 days or subcutaneous betrixaban 40 mg once daily for 10 AE 4 days [12] . Patients with severe renal insufficiency (creatinine clearance of < 30 mL min À1 ) or being treated with a concomitant strong P-glycoprotein inhibitor received a reduced-dose regimen of betrixaban (40 mg once daily). The primary efficacy endpoint was a composite of asymptomatic proximal DVT between day 32 and day 47, symptomatic proximal or distal DVT, symptomatic non-fatal PE, or death from VTE between day 1 to day 42. The principal safety outcome was the occurrence of major bleeding at any point until 7 days after discontinuation of study medications.
Statistical analysis
The analysis assessed the efficacy-safety tradeoff between symptomatic VTE (a composite of symptomatic DVT, PE, and VTE-related mortality) and major bleeding on the basis of on study-level data from the publications for the EXCLAIM, ADOPT, MAGELLAN and APEX trials. The detailed methodology of bivariate analysis has been previously described [8] . In brief, the risk differences in efficacy (RD E ) and safety (RD S ) were calculated by subtracting the event rate for standard-duration enoxaparin from the event rate for extended-duration thromboprophylaxis. A bivariate two-dimensional plane was thus defined by RD E and RD S , with the lower left quadrant representing reductions in both symptomatic VTE and major bleeding risks with extended-duration treatment ( Fig. 1 ). The 95% confidence interval (CI) of risk difference on the efficacy and safety endpoint for each trial was summarized as a rectangle on the bivariate plane. A multiplicative definition of NCB was considered as:
where:
A E ¼ horizontal asymptote for the efficacy endpoint A S ¼ vertical asymptote for the safety endpoint W E ¼ weighting factor for the efficacy endpoint W S ¼ weighting factor for the safety endpoint
Derivation of the NCB curve
A clinically important risk difference was set at 2.00% for both efficacy and safety events to approximate the maximum effect size among the extended-duration thromboprophylactic agents. The non-inferiority efficacy margin of 9% (equivalent to an absolute risk difference of 0.18%, i.e. from 2.00% to 2.18%) was derived from preserving 50% of the treatment effect of standard-duration enoxaparin dosed at 40 mg once daily against placebo based on previous studies [13] [14] [15] in the random-effects model [16] with the fixed margin method [14] (Data S1). The non-inferiority safety margin was set at 25% (equivalent to an absolute risk difference of 0.50%, i.e. from 2.00% to 2.50%) in accordance with the original publication [8] . The parameters A E , A S , W E , and W S were subsequently solved to derive the NCB curve representing the null hypothesis.
Qualitative and quantitative assessment of the bivariate outcome
The NCB curve divided the bivariate plane into two regions. The lack-of-benefit region was defined as the part above the curve. The risk-benefit profile was deemed to be favorable against standard-of-care enoxaparin if the 95% CI rectangle did not contain the lack-of-benefit region. The qualitative inference obtained with the multiplicative NCB definition was compared with the conventional NCB definition. Furthermore, bivariate outcomes were quantitatively assessed according to the minimum distance from the NCB curve to three reference points: (i) center of the confidence rectangle; (ii) southwest corner of the confidence rectangle representing the lower boundary of the 95% CI; and (iii) northeast corner of the confidence rectangle representing the upper boundary of the 95% CI (Fig. 2) . Accordingly, the bivariate outcome (the collective treatment effect on symptomatic VTE and major bleeding) was expressed as an observed risk difference along with a range of corner distance (CD). These metrics were analogous to reporting the point estimate with a 95% CI; that is, positive values indicate an increased risk and negative values indicate a decreased risk.
Sensitivity analysis of the non-inferiority margin
The NCB was compared in three sensitivity analyses to test a spectrum of non-inferiority margins ranging from 10% to 50%. In the first sensitivity analysis, the noninferiority margin for safety was maintained at 25%, and the efficacy margin ranged from 10% to 50%. In the second sensitivity analysis, the non-inferiority margin for efficacy was maintained at 9%, and the safety margin ranged from 10% to 50%. In the third sensitivity analysis, paired margins for efficacy and safety ranging from 10% to 50% were used.
Sensitivity analysis of weighing VTE against major bleeding
The four included trials universally included asymptomatic DVT as one of the components of the primary efficacy outcome. In view of this, a sensitivity analysis weighing VTE (a composite of asymptomatic and symptomatic DVT, PE, and VTE-related mortality) against major bleeding was also performed.
Results
Summary of trial results
Four double-blind, double-dummy, randomized controlled trials were included. The analyzed data encompassed 28 227 patients randomized to receive extendedduration thromboprophylaxis with enoxaparin, apixaban, rivaroxaban or betrixaban versus standard-duration enoxaparin for VTE prevention. The efficacy and safety event rates are summarized in Table 1 .
Qualitative assessment of the bivariate outcome
Trial results were expressed as a rectangle defined by the 95% CI of risk difference in symptomatic VTE and in major bleeding in the bivariate plane (Fig. 3) . Rectangles for the EXCLAIM, ADOPT and MAGELLAN trials and the full-dose regimen from the APEX trial clustered within the lower right quadrant, suggesting that the reduction in VTE risk generally came at the cost of an increase in the major bleeding risk. The 0.00% horizontal Lack-of-benefit region Southwest corner Fig. 2 . Interpretation of the bivariate outcome. Qualitatively, a favorable net clinical benefit (NCB) is established if the rectangle defined by the 95% confidence interval of risk difference does not include the lack-of-benefit region. Quantitatively, the bivariate outcome is measured according to the minimum distance from the NCB curve to the center and opposing corners of the confidence rectangle. The minimum distances to the center, northeast corner and southwest corner represent the point estimate, lower bound and upper bound of the bivariate outcome. CI, confidence interval; DVT, deep vein thrombosis; ED, extended-duration; NI, non-interpretable; NNH, number needed to harm; NNT, number needed to treat; PE, pulmonary embolism; SD, standard-duration. *NNT or NNH was deemed to be NI for regimens that did not show a significant risk difference. †Although the majority of APEX study participants did not require dose adjustment, and received full-dose betrixaban (80 mg once daily), patients with severe renal insufficiency or being treated with a concomitant strong P-glycoprotein inhibitor received reduced-dose betrixaban (40 mg once daily).
for apixaban, rivaroxaban and reduced-dose betrixaban crossed the horizontal line, indicating that superiority in VTE risk reduction was not achieved. All extended-duration regimens except for reduced-dose betrixaban achieved non-inferiority with respect to VTE risk reduction. With respect to safety, the rectangles for all four trials either crossed or were on the right of the vertical line, indicating that these agents failed to achieve superiority in major bleeding risk reduction. Indeed, extended-duration enoxaparin, apixaban and rivaroxaban were significantly inferior to standard prophylaxis with enoxaparin with respect to major bleeding risk reduction (the 95% CIs did not overlap and lay to the right of the vertical line). Similarly, the 0.18% horizontal asymptote and 0.50% vertical asymptote represented the non-inferiority margins for efficacy and safety, respectively. Only fulldose betrixaban achieved non-inferiority with respect to major bleeding risk reduction.
In terms of the multiplicative NCB, only the rectangle for full-dose betrixaban did not include the lack-of-benefit region, indicating that only extended-duration betrixaban at 80 mg daily had a favorable risk-benefit profile versus standard-of-care enoxaparin. When they were evaluated under the conventional NCB framework, which assumes a 1 : 1 tradeoff between symptomatic VTE and major bleeding, none of the extended-duration regimens was preferable to standard-duration enoxaparin (Fig. S4) .
Quantitative assessment of the bivariate outcome Quantitatively, bivariate outcomes were assessed according to the minimum distance from the NCB curve to the center and opposing corners of the rectangle (Fig. 4) . Extended-duration enoxaparin (0.03%; CD À 0.37% to 0.43%), apixaban (À 0.20%; CD À 0.49% to 0.17%), rivaroxaban (0.23%; CD À 0.16% to 0.69%) and reduced-dose betrixaban (0.41%; CD À 0.85% to 1.94%) did not significantly improve NCB. Only full-dose betrixaban (À 0.51%; CD À 0.89% to À 0.10%) showed a significantly favorable risk-benefit profile relative to standard-duration enoxaparin.
Sensitivity analysis of the non-inferiority margin
Sensitivity analyses with a range of non-inferiority margins are shown in Figs S5-S20. In the first sensitivity analysis, in which the safety margin was fixed at 25%, only full-dose betrixaban showed a favorable NCB profile. In the second sensitivity analysis, in which the efficacy margin was fixed at 9%, extended-duration enoxaparin, apixaban and full-dose betrixaban showed a favorable NCB when the non-inferiority safety margin reached 50%, 40%, and 20%, respectively. In the third sensitivity analysis, apixaban and full-dose betrixaban showed a favorable NCB with efficacy and safety margins of 40% and 20%, respectively. 
Sensitivity analysis of weighing VTE against major bleeding
A sensitivity analysis evaluating the tradeoff between VTE (a composite of asymptomatic and symptomatic DVT, PE, and VTE-related mortality) and major bleeding is shown in Figs S21 and S22 . Extended-duration enoxaparin and rivaroxaban were both superior to standardduration enoxaparin with respect to efficacy, but did not achieve non-inferiority with respect to safety, and therefore were not favorable with respect to NCB (respectively: À 0.21%, CD À 0.62% to 0.23%; and À 0.01%, CD À 0.41% to 0.45%). Apixaban was non-inferior in efficacy, was inferior in safety, and was not favorable with respect to NCB (À 0.35%; CD À 0.70% to 0.26%). Betrixaban was superior in efficacy, was non-inferior in safety, and showed a favorable NCB (À 0.61%; CD À 1.00% to À 0.20%).
Discussion
Although the risk of VTE may remain elevated for weeks to months after hospital discharge, the optimal duration and regimen of thromboprophylaxis for acutely ill hospitalized medical patients continue to be debated. Extended-duration thromboprophylaxis refers to prophylaxis that extends beyond the initial course of 10 AE 5 days through approximately 35 days. The riskbenefit profile of extended-duration treatment with the novel oral anticoagulants versus standard-of-care enoxaparin in the prevention of VTE in medically ill patients has not been comprehensively evaluated. The present study excluded asymptomatic VTE events and weighed symptomatic VTE events against major bleeding events in order to compare the NCBs of extended-duration enoxaparin, apixaban, rivaroxaban, and betrixaban. Extended prophylaxis with full-dose betrixaban showed a favorable NCB than standard-duration enoxaparin, with a significant favorable risk difference of À 0.51% (À 0.89% to À 0.10%) in a bivariate analysis. Among the regimens that failed to achieve a favorable NCB, extended-duration enoxaparin was superior in efficacy but inferior in safety, whereas apixaban and rivaroxaban were both non-inferior in efficacy and inferior in safety. Reduced-dose betrixaban was administered to a subgroup of patients with severe renal insufficiency or being treated with a concomitant strong P-glycoprotein inhibitor, and did not show a significant difference in efficacy or safety.
Bivariate analysis is a novel statistical method that allows simultaneous assessment of efficacy and safety endpoints based upon clinical relevant and potentially asymmetric statistical margins for efficacy and safety. The output includes a qualitative comparison of the efficacysafety rectangle of the 95% CI with the NCB curve displayed on the risk-benefit plane based on a structured definition of non-inferiority, and a quantitative comparison of risk reduction in the bivariate outcome illustrated in a forest plot based on the minimum distance from the NCB curve to the rectangle. The qualitative and quantitative inferences may be affected by the choice of non-inferiority margin. Therefore, a standardized method for determining the appropriate margin is crucial for establishing the NCB [14] . A sensitivity analysis in which the non-inferiority bound is varied can be performed to examine the robustness of the bivariate outcome. In the present sensitivity analyses, in which a clinically important risk difference was set at 2.00% for both symptomatic VTE and major bleeding, full-dose betrixaban consistently achieved a favorable NCB when the safety margin was set at ≥ 20%. In other words, if a 0.40% threshold of risk difference in major bleeding is clinically acceptable, full-dose betrixaban for 35-42 days is preferred over enoxaparin for 10 AE 4 days with respect to NCB.
For the currently available extended-duration thromboprophylaxis to reach a favorable NCB would require reduction in symptomatic VTE risk while an acceptable rate of major bleeding is maintained. The advantage of a bivariate analysis is that it does not assume a linear or constant tradeoff in efficacy versus bleeding across a wide range of efficacy and bleeding event rates, and allows for asymmetry in the statistical margins for efficacy and bleeding. It yields one number that can be used to compare regimens across trials (the bivariate outcome). Given the inherent risk of bleeding associated with anticoagulants, it is difficult at this time to believe that an anticoagulation regimen would be superior to the standard of care with respect to not only efficacy but also safety outcomes. Indeed, extended-duration enoxaparin, apixaban and rivaroxaban were significantly inferior to standard-duration enoxaparin with respect to major bleeding. Betrixaban, however, has unique pharmacokinetic properties that differentiate it from these agents, including a longer halflife with a lower peak-to-trough plasma concentration ratio and the lowest renal clearance among any of these agents, which may improve the safety profile in an elderly population such as acutely ill hospitalized medical patients [17, 18] . Perhaps it is, at least in part, because of these unique pharmacokinetic characteristics that fulldose betrixaban was non-inferior to standard-duration enoxaparin with respect to major bleeding. Although this study was performed after trial completion as a post hoc exploratory analysis, the bivariate method has been applied in clinical trial design and interim analyses. In these circumstances, the efficacy and safety components of the bivariate outcome are customized according to their clinical impact. For instance, in the Kids-DOTT trial (ClinicalTrials.gov identifier: NCT00687882), which aims to evaluate the duration of anticoagulation in children with first-episode acute venous thrombosis, a bivariate endpoint is used as the primary outcome measure, in which the efficacy component is the risk of symptomatic, radiologically confirmed recurrent VTE, and the safety component is clinically relevant bleeding. In addition, the bivariate method has been used in devising the stopping criteria for the interim analyses [6] . In the MARINER trial (ClinicalTrials.gov identifier: NCT02111564), which compares the efficacy and safety of rivaroxaban versus placebo for VTE prevention in highrisk medically ill patients, the prespecified analyses include the bivariate approach to assess the risk-benefit profile with symptomatic VTE or VTE-related death as the efficacy component and major bleeding as the safety component [7] . In the present context of acutely ill hospitalized medical patients, although the primary efficacy endpoint of recent trials was the composite of asymptomatic and symptomatic DVT, PE, and VTE-related death, the clinical relevance of the asymptomatic DVT remains controversial [19] . It is for this reason that only symptomatic events were included in the present analysis, and the treatment benefit of reducing symptomatic VTE events was weighed against major bleeding in light of their comparable clinical significance and mortality rates.
Future studies are warranted to systematically assess the clinical impact of both asymptomatic DVT and nonmajor bleeding events in this population.
Conclusions
Bivariate analysis is a novel method that allows collective assessment of efficacy and safety endpoints with considerations on the non-inferiority margins. In the management of acutely ill hospitalized medical patients, extended prophylaxis with full-dose betrixaban was superior to standard-duration enoxaparin, whereas other regimens failed to simultaneously achieve both superiority and non-inferiority with respect to symptomatic VTE and major bleeding. 
Supporting Information
Additional Supporting Information may be found in the online version of this article: Fig. S1 . Conventional net clinical benefit with a linear, symmetric, and unlimited risk-benefit tradeoff of 1 : 1 ratio (for example, a 1-unit improvement in efficacy endpoint is offset by a 1-unit worsening in safety endpoint). Fig. S2 . Conventional net clinical benefit with a linear, symmetric, and unlimited risk-benefit tradeoff of 2 : 1 ratio (for example, a 1-unit improvement in efficacy endpoint is offset by a 2-unit worsening in safety endpoint). Fig. S3 . Net clinical benefit with a non-linear and asymmetric risk-benefit tradeoff defined by the acceptable worsening in safety/efficacy endpoint when clinically meaningful improvement in efficacy/safety endpoint is achieved. Fig. S4 . Conventional net clinical benefit with a 1 : 1 tradeoff between symptomatic VTE and major bleeding among acutely ill hospitalized medical patients. Fig. S5 . Sensitivity analysis of the non-inferiority margin. Fig. S6 . Sensitivity analysis 1: EXCLAIM. Fig. S18 . Sensitivity analysis 1: APEX (reduced-dose). Fig. S19 . Sensitivity analysis 2: APEX (reduced-dose). Fig. S20 . Sensitivity analysis 3: APEX (reduced-dose). Fig. S21 . Bivariate outcome of VTE and major bleeding among acutely ill hospitalized medical patients. Fig. S22 . Forest plot of the bivariate outcomes (expressed as the minimum distance from the net clinical benefit curve to the rectangle defined by the 95% confidence interval of risk difference in VTE and in major bleeding). Data S1. Supplementary data.
